NASDAQ: AYTU · Life Sciences · 4 alerts · CIK 1385818
Share price
$1.82Close, Nov 16
Market cap
$19.8M
Shares outstanding
10.87MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834
Today's reference numbers: shares from the company's latest SEC cover page, price from the latest market close. Not a valuation or a recommendation. All Aytu Biopharma, Inc filings on SEC EDGAR ↗
Aytu BioPharma reported significant warrant reclassifications from liability to equity following amendments in March 2026. The company maintains a $3.8 million Employee Retention Credit accrual and continues to manage debt through an Eclipse Business Capital loan agreement, while focusing on its ADHD and Pediatric portfolios.
Aytu Biopharma Signs $56M M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals Holdings, Inc. for $2.70 per share in cash, representing a total deal value of approximately $56 million. The transaction will be structured as a cash tender offer followed by a merger and is expected to close by the end of calendar 2026. The company also reported Q1 fiscal 2027 revenue of $14.8 million alongside the merger announcement.
Value
$56M
Counterparty
Rosemont Pharmaceuticals Holdings, Inc.
“Today, we announced that Aytu has entered into a definitive agreement to be acquired by Rosemont for $2.70 per share in cash. This agreement with Rosemont reflects the work our team has done to build our CNS and pediatric portfolio and earn the trust of the patients and healthcare providers we serve.”
Josh Disbrow, Chief Executive Officer of Aytu
“Importantly, we believe the transaction delivers compelling value to our shareholders and that, together, we can help more patients get the treatment they need.”
Aytu Biopharma M&A Deal with Rosemont Pharmaceuticals Holdings, Inc.
Aytu BioPharma has entered into a definitive agreement to be acquired by Rosemont Pharmaceuticals for $2.70 per share in an all-cash tender offer. The deal represents a 51.7% premium to Aytu's closing price on November 13, 2026, and is expected to close by the end of 2026. Upon completion, Aytu will become a wholly owned subsidiary of Rosemont, supporting Rosemont's U.S. growth strategy in the CNS and pediatric specialty pharmaceutical markets.